Susan Horvath
2021
In 2021, Susan Horvath earned a total compensation of $557.1K as Chief Financial Officer and Vice President of Finance at Panbela Therapeutics, a 35% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $99,620 |
|---|---|
| Option Awards | $155,258 |
| Salary | $302,200 |
| Total | $557,078 |
Horvath received $302.2K in salary, accounting for 54% of the total pay in 2021.
Horvath also received $99.6K in non-equity incentive plan and $155.3K in option awards.
Rankings
In 2021, Susan Horvath's compensation ranked 10,484th out of 12,415 executives tracked by ExecPay. In other words, Horvath earned more than 15.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,484 out of 12,415 | 16th |
Division Manufacturing | 4,642 out of 5,505 | 16th |
Major group Chemicals And Allied Products | 2,081 out of 2,375 | 12th |
Industry group Drugs | 1,845 out of 2,096 | 12th |
Industry Pharmaceutical Preparations | 1,369 out of 1,546 | 11th |
Source: SEC filing on April 29, 2022.
Horvath's colleagues
We found two more compensation records of executives who worked with Susan Horvath at Panbela Therapeutics in 2021.